pcn poster

Posters

Annual Cost of Major Depressive Disorder and Impact of Key Clinical Events

BACKGROUND: Patients with major depressive disorder (MDD) who experience clinical events of interest (EOIs) such as suicide attempt/ideation and hospitalization may incur greater costs. T...

Rakesh Jain , MD, MPH, RD;

Julie Park , BA, MPH;

Andrew J. Cutler , MD;

Sara Higa , PharmD, MS;

Machaon Bonafede , PhD, MPH;

Patrick Gillard , PharmD, MS;

Katelyn Keyloun , PharmD, MS;

11/22/2019

Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study

BACKGROUND: Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dysregulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist s...

Christoph U. Correll , MD;

11/22/2019

Efficacy and Cost Analysis of Assisted Outpatient Treatment Program for Severely Mentally Ill Patients in a Small Alabama Community

Involuntary outpatient commitment (OPC) is a civil court procedure intended to aid persons with severe mental illness who require more intensive intervention to adhere to outpatient treat...

Praveen Narahari , MD;

Bradley Brooks , DO;

Cindy Gipson , PhD;

Michael Marshall , MD;

Sandra Parker , MD;

11/22/2019

Demographic Characteristics, Healthcare Cost, and Treatment Patterns Among Patients With Major Depressive Disorder and Suicidal Ideation or Suicide Attempt Who Received Treatment at a Hospital

Introduction: Major Depressive Disorder (MDD) is a leading cause of disability and a major risk factor for suicide. MDD patients who are suicidal(MDD+SI) are often evaluated in the emerge...

Qiaoyi Zhang , MD, PhD;

Nancy Connolly , MPH;

Ali Bonakdar , PhD, PharmD, MPH;

Bingcao Wu , PhD, MS;

11/22/2019

Efficacy of Monthly Extended-release Risperidone Injections (RBP-7000) for the Treatment of Schizophrenia: An Analysis of Individual PANSS Items

Introduction: RBP-7000 (PERSERIS™) is a once-monthly, subcutaneous, extended-release risperidone formulation that is approved for treating schizophrenia in adults and is designed to deliv...

Anne Andorn , MD;

James Graham , PharmD, BS Pharm, RPh;

Maurizio Fava , MD, PhD;

John Csernansky , MD;

John Newcomer , MD;

Sunita Shinde , MD;

Gilbert Muma , PhD;

Christian Heidbreder , PhD;

David Walling , PhD, CNS, MD;

11/22/2019

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

Edward S. Kim , MD, FACP, MBA;

Patrick Lefebvre , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Bruno Emond , MA;

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

11/22/2019

Evaluation of Depression Severity Items on the Patient Health Questionnaire (PHQ-9) and Sheehan Disability Scale (SDS) in Patients With Treatment-Resistant Depression Treated With Esketamine Nasal Spray

Introduction: Major depressive disorder is a leading cause of disability and about 30% of patients are diagnosed with treatment-resistant depression (TRD) after failing two pharmacologica...

Lysbeth Floden , PhD;

Vanina Popova , MD;

Stacie Hudgens , MA, MSc;

Kimberly Cooper , MS;

Wayne Drevets , MD;

Jaskaran Singh , MD;

Carol Jamieson , BSc;

11/22/2019

Repetitive Transcranial Magnetic Stimulation as a Protective Measure Against Early-Onset Alzheimer’s Disease: A Case Report

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease leading to cognitive decline and death. Degradation of cortical neuroplasticity is implicated as a major ca...

Martin Knoll , BS;

Margaret Swanberg , DO;

Jared Garland , BS;

Emilia-Marie Jaskot , BS;

Jerika Taylor , MA;

Kiara Buccellato , MA;

Paul Pasquina , MD;

Megan Tsui , BS;

11/22/2019

Number Needed to Treat Analysis of the SAGE-217 Phase 2 Clinical Trial Results in Major Depressive Disorder

Background: SAGE-217 is a novel, positive allosteric modulator of GABA(A) receptors under development in Major Depressive Disorder (MDD). This analysis quantified the number needed to tre...

Ken O'Day , PhD, MPA;

Vijayveer Bonthapally , PhD;

Alix Arnaud , MSc;

Ellison Suthoff , MBA, BS ;

Katie Stenson , MSc;

Brian Werneburg , PhD;

Paul Hodgkins , PhD, MSc;

Jeffrey Jonas , MD;

Kellie Meyer , PharmD, MPH;

11/22/2019

Post Hoc Responder Analyses of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults With Attention-Deficit/Hyperactivity Disorder

In adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release reduced ADHD-Rating Scale-IV total score (ADHD-RS-IV-TS) significantl...

Lenard Adler , MD;

Elias Sarkis , MD;

Richard Able , PhD;

Jie Chen , MS;

Brigitte Robertson , MD;

11/22/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products